The patent is for the company's minimally invasive device for the cryoablation treatment of benign breast tumors.
IceCure Ltd. (TASE: ICCM) has received another patent from the US Patent and Trademark Office for the company's minimally invasive device for the cryoablation treatment of fibroadenoma (benign breast tumors) - IceSense3. The patent is valid through May 2030.
The treatment applies the liquid phase of nitrogen to freeze the tumor, and the gaseous phase to heat and thaw the needle to release it at the end of the procedure without the need of electrical current.
IceCure already has US seven patents for its cyroablation system.
IceCure's share price rose 1.5% by early afternoon to NIS 6.80, after rising over 5% in morning trading, giving a market cap of NIS 88 million.
Published by Globes [online], Israel business news - www.globes-online.com - on June 14, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011